Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-544.00 · Revenue $660000.00 · 1 analysts
Est. EPS $-527.00 · Revenue $640000.00 · 1 analysts
Est. EPS $-187.00 · Revenue $520000.00 · 1 analysts
Est. EPS $-136.00 · Revenue $630000.00 · 1 analysts
EPS $-2.19 · Revenue $86000.00
EPS $-2.52 · Revenue $70000.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $382000 | -51.0% | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-8.9M | -57.0% | -14.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | -1.3% | -610.5% | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -2067.5% | -184.9% | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -2324.1% | -220.6% | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-7.6M | -32.4% | -5.7% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -1984.3% | -170.3% | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 38.4% | — | -45.2% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 20.13x | +107.5% | -66.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $31.6M | +1026.0% | -15.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | — | — | -2.10 vs -544.00 | +99.6% |
| Revenue Surprise | $382000 vs $8.0M | -95.2% | $0 vs $660000 | -100.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Apr 15, 2026 | Bolton Sheryle | director | Common Stock | A | 10,000 | $1.04 |
| Apr 1, 2026 | Valauri Christina Rizopoulos | director | Common Stock | A | 19,000 | $0.95 |
| Mar 18, 2026 | Wolf Lisa G | officer: Chief Financial Officer | Restricted Stock Units | D | 92 | — |
| Mar 18, 2026 | Wolf Lisa G | officer: Chief Financial Officer | Common Stock | A | 92 | — |
| Feb 18, 2026 | Handley Michael K | officer: Chief Operating Officer | Restricted Stock Units | D | 8,824 | — |
Operator: Welcome to Tivic Health Systems third quarter 2025 financial results and operational update conference call. This call has been prerecorded. This call is being webcast, and the replay will be available on the IR of the company's website for three months. Before we begin, let me remind you that during today's call, management will make various forward-looking statements. Investors are cautioned that these forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those indicated in our forward-looking statement. Please read the safe harbor statement contained in the press release that Tivic Health issued today as well as the risk factors contained in Tivic Health's filings with the SEC, including its annual report on Form 10-K of the year ended 12/31/2024 and the Form 10-Q to be filed with the SEC today as well as other companies' SEC filings. Hosting today's call is Jennifer Ernst, Tivic CEO, and Lisa Wolf, Tivic CFO. Now let me turn the call over to Jennifer Ernst. Thank you, and welcome to everyone listening today. Jennifer Ernst: I'm pleased to be reporting on the progress we have made during the third quarter in building a new Tivic. As many of you know, at the start of the year, we undertook a significant strategic transformation of Tivic Health Systems, Inc. Beginning in February, with the licensing of entolimod and related assets, we expanded from bioelectronics to biologic pharmaceuticals with a common focus on the immune system and the ways we can harness the immune system to improve clinical outcomes and save lives. We've accomplished a great deal in a very short time. In Q2, we built out the team and secured the first meetings with potential customers for Entelimod's use as a military countermeasure. We continue to deepen those connections and expect to be meeting with BARDA in the coming months to discuss stockpiling opportunities. While our commercial focus is squarely on moving Intaloupe through our first BLA with the FDA for acute radiation syndrome, we've also continued to enrich our pipeline. We licensed Entelimod and Entelasta for neutropenia and have begun discussions with leading institutions about conducting investigator-led studies in this area. We have filed new intellectual property, IP that supports the potential use of our TLR5 agonist as adjunctive therapies for immuno-oncology cancer therapeutics. We have completed the optimization study for our VNS device design, uncovering the key parameters that have the strongest influence on the autonomic nervous system activity. And we are completing the exit from the consumer health market, increasing focus on prescription therapeutics. Today, let me focus more on our fully licensed entolimod portfolio and report to you where this drug candidate stands from a clinical development perspective. Entalimod itself is a first-in-class late-stage, highly …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Lisa G. Wolf | Chief Financial Officer and Principal Financial & Principal Accounting Officer | USD 333,978 | Female | 1964 | Active |
Jennifer Ernst | Co-Founder, Chief Executive Officer & Director | USD 317,456 | Female | 1968 | Active |
Michael Kevin Handley | CEO & Director | USD 293,922 | Male | 1972 | Active |
The article provides an earnings forecast for Tivic Health Systems Ord Shs (VBIO), detailing future EPS and revenue growth estimates. It includes current stock price information, market capitalization, and a peer comparison section with other healthcare equipment companies. The data was last updated on August 8, 2026.
This article provides a detailed financial overview of Tivic Health Systems Ord Shs (VBIO), including its current stock price, market capitalization, key figures, and performance indicators. It highlights significant fluctuations in its stock price, indicators for sell and oversold signals, and lists major shareholders, though it notes that key financial data like EPS and total revenue have not yet been disclosed by the company. The article also includes related instruments and popular market indices.
This article provides an earnings forecast for Tivic Health Systems Inc (TIVC), noting that no earnings forecast score is currently available for the company, while the industry average is 7.80. It states that relevant data concerning financial forecasting for EPS, revenue, and net profit have not yet been disclosed by the company. The article also provides the current stock price and market capitalization for TIVC.
This article provides an overview of Tivic Health Systems Inc (TIVC), focusing on its revenue breakdown. However, the data for business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The page displays current stock information and notes the absence of detailed financial breakdown data.
This article details the shareholder structure of Tivic Health Systems Inc (TIVC), providing a breakdown of major shareholders, institutional holdings, and an overview of shareholder activity. It lists the proportion of shares held by various entities like Avenue Capital Group, Geode Capital Management, and Sanctuary Advisors, along with historical institutional ownership data and changes in holdings over specific reporting periods.
